Expanding Treatment Options for an Aggressive Breast Cancer
The FDA has approved a new targeted therapeutic for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies....
Progress Against Cancer
The FDA has approved a new targeted therapeutic for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies....
Researchers estimate that breast cancer surpassed lung cancer as the most commonly diagnosed cancer globally in 2020, and more...
A study indicates that some breast cancer patients who receive mastectomy and reconstruction may be at risk of persistent...
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast...
The FDA granted approval to expand the use of a minimally invasive biomarker test to identify certain patients with ovarian,...
Socioeconomic factors and racism can lead to poorer health outcomes for Black Americans.
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast...
A new study suggests that a HER2-targeted therapy approved for breast cancer may be effective for several other cancers....
A new study finds that Latina women with a higher proportion of Indigenous American ancestry may be at increased...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Now